세계의 휴미라 바이오시밀러 시장 : 제품별, 적응증별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2023-2030년)

Humira Biosimilar Market, By Product, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

US $ 3,250 ￦ 4,490,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,650 ￦ 6,424,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650 ￦ 7,806,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

보고서 하이라이트

휴미라 바이오시밀러(Humira Biosimilar) 시장 규모는 2022년 7억 9,010만 달러였으며, 2023년부터 2030년까지 CAGR 20.9%로 추이하며 성장 할 것으로 예상됩니다.

휴미라 바이오시밀러 시장-시장 역학 :

• 자가면역질환의 유행과 생물학적 치료에 대한 수요 증가
• 휴미라 바이오시밀러 시장은 특정 지역에서 휴미라의 특허가 만료됨에 따라 다른 제약 회사들이 시장에 진입하여 보다 저렴한 버전의 약품을 생산할 수 있게 됨에 따라 크게 성장하고 있습니다. 바이오시밀러는 레퍼런스 의약품에 대한 비용 효율적인 대안을 제공하여 환자의 치료 접근성을 높이고 의료비 지출을 줄입니다. 또한 자가면역 질환의 유병률 증가와 생물학적 치료제에 대한 수요 증가는 휴미라 바이오시밀러에 대한 수요를 촉진했습니다.
• 세계적으로 자가면역질환 증가와 그에 따른 건강관리 지출의 급증을 받고 연구·진단기관은 정부기관과 연계한 대처를 실시했습니다. 미국 국립위생연구소(NIH)의 데이터에 따르면 자가면역질환은 여성 사망률 상승의 원인 상위 10위에 있습니다. 그 결과 이러한 건강 과제를 해결하기 위해 연구 기관과 정부 기관의 협력을 통해 노력하고 있습니다.

휴미라 바이오시밀러 시장-세분화 분석 :

• 휴미라 바이오시밀러 시장은 제품, 적응증, 지역별로 구분됩니다.
• 휴미라 바이오시밀러 시장은 제품, 적응증, 지역별로 구분됩니다 : 레퍼런스 기반 바이오시밀러, 아미노산 서열 수정 바이오시밀러, 호환 가능 바이오시밀러입니다. 2022년에는 기준 기반 바이오시밀러가 시장을 독점할 것으로 예상됩니다. 레퍼런스 기반 바이오시밀러는 레퍼런스 의약품인 휴미라(아달리무맙)와 특성과 성능을 직접 비교하여 개발됩니다. 유사한 세포주 및 제조 방법을 사용하여 제조되므로 유사성이 높은 제품을 얻을 수 있습니다.
• 시장은 적응증에 따라 네가지 범주로 나뉩니다. 류마티스 관절염, 건선, 크론병 및 기타입니다. 류마티스 관절염 치료 부문은 수익에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 류마티스 관절염은 신체의 면역 체계가 관절을 둘러싸고있는 막의 내막 인 활막을 잘못 공격하는자가 면역 질환입니다. 이로 인해 만성 염증이 발생하여 관절 손상, 통증, 부기 및 뻣뻣함을 유발합니다.
• 아달리무맙은 TNF-α를 차단함으로써 염증을 줄이고 관절 손상의 진행을 늦춰 류마티스 관절염의 증상을 완화하고 환자의 삶의 질을 개선하는 데 도움을 줍니다. 휴미라 바이오시밀러는 류마티스 관절염 치료에 사용되는데, 그 이유는 기준 약물인 휴미라(아달리무맙)와 매우 유사한 활성 성분을 함유하고 있기 때문입니다. 아달리무맙은 류마티스 관절염에서 관절에 염증을 일으키는 데 중요한 역할을 하는 단백질인 종양괴사인자 알파(TNF-α)를 특이적으로 표적하여 억제하는 단일 클론 항체입니다.

휴미라 바이오시밀러 시장-지리적 통찰력 :

휴미라 바이오시밀러 시장은 북미, 남미, 유럽, 아시아 태평양, 중동 및 아프리카에 널리 분포되어 있습니다. 이 지역은 비즈니스를 전개하는 국가에 따라 더욱 세분화됩니다.

휴미라 바이오시밀러 시장-경쟁 구도 :

휴미라 바이오시밀러 시장 진출기업들은 경쟁 우위를 차지하기 위해 다양한 전략을 채택하고 있습니다. 이를 위해서는 바이오시밀러의 품질과 효능을 확보하기 위한 광범위한 조사개발에 투자, 보완적인 전문지식을 활용하기 위한 전략적 제휴와 협력관계 구축, 신시장 접근에 대한 지리적 존재의 확대 등이 포함됩니다. 또한 매력적인 가격 모델과 우수한 애프터 서비스를 제공함으로써 더 많은 고객을 확보하고 시장 점유율을 높이는 데 주력하는 기업도 있습니다.

목차

제1장 휴미라 바이오시밀러 시장 개요

• 조사 범위
• 시장 추정 연도

제2장 주요 요약

• 시장 분석
• 경쟁 인사이트

제3장 휴미라 바이오시밀러-주요 시장 동향

• 시장 성장 촉진 요인
• 시장 성장 억제 요인
• 시장 기회
• 향후 시장 동향

제4장 휴미라 바이오시밀러 산업 조사

• PEST 분석
• Porter's Five Forces 분석
• 성장 전망 맵핑
• 규제 프레임워크 분석

제5장 휴밀라 바이오시밀러 시장 : COVID-19 영향 분석

• COVID-19 이전 영향 분석
• COVID-19 이후 영향 분석

제6장 휴미라 바이오시밀러 시장 상황

• 휴미라 바이오시밀러 시장 점유율 분석(2022년)
• 주요 제조사별 분석 데이터
  • 기존 기업 분석
  • 신흥 기업 분석

제7장 휴미라 바이오시밀러 시장-제품별

• 개요
  • 제품별 부문 점유율 분석
  • 레퍼런스 기반 바이오시밀러
  • 아미노산 서열 수정 바이오시밀러
  • 호환 가능 바이오시밀러

제8장 휴미라 바이오시밀러 시장-적응증별

• 개요
  • 적응증별 부문 점유율 분석
  • 류마티스 관절
  • 건선
  • 크론병
  • 기타

제9장 휴미라 바이오시밀러 시장-지역별

• 소개
• 북미
  • 개요
  • 북미의 주요 제조사
  • 미국
  • 캐나다
• 유럽
  • 개요
  • 유럽의 주요 제조사
  • 독일
  • 이탈리아
  • 영국
  • 프랑스
  • 러시아
  • 네덜란드
  • 스웨덴
  • 폴란드
  • 기타
• 아시아 태평양(APAC)
  • 개요
  • 아시아 태평양의 주요 제조사
  • 인도
  • 중국
  • 일본
  • 한국
  • 호주
  • 태국
  • 인도네시아
  • 필리핀
  • 기타
• 남미
  • 개요
  • 남미의 주요 제조사
  • 브라질
  • 멕시코
  • 아르헨티나
  • 콜롬비아
  • 기타
• 중동 및 아프리카
  • 개요
  • 중동 및 아프리카의 주요 제조사
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 이스라엘
  • 터키
  • 알제리
  • 이집트
  • 기타

제10장 주요 벤더 분석-휴미라 바이오시밀러 산업

• 경쟁 대시보드
• 기업 개요
  • Amgen
  • Samsung Bioepis
  • Sandoz(a division of Novartis)
  • Mylan(now part of Viatris)
  • Boehringer Ingelheim
  • Pfizer
  • Fresenius Kabi
  • Coherus BioSciences
  • Merck &Co.

제11장 애널리스트의 전방위 전망

LYJ

영문 목차

영문목차

REPORT HIGHLIGHT

Humira Biosimilar Market size was valued at USD 790.1 Million in 2022, expanding at a CAGR of 20.9% from 2023 to 2030

Humira biosimilars are biologic drugs that are highly similar to the reference biologic drug Humira (adalimumab). Adalimumab is a monoclonal antibody that targets tumor necrosis factor alpha (TNF-α) and is used to treat various autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. Biosimilars are developed to be comparable in terms of safety, efficacy, and quality to the original drug but are manufactured by different companies after the patent of the reference drug has expired.

Humira Biosimilar Market - Market Dynamics:

• Increasing prevalence of autoimmune diseases and the rising demand for biologic treatments

• The Humira biosimilar market is experiencing significant growth due to the expiration of Humira's patents in certain regions, allowing other pharmaceutical companies to enter the market and produce more affordable versions of the drug. Biosimilars offer cost-effective alternatives to the reference drug, making treatment more accessible to patients and reducing healthcare expenditures. Additionally, the increasing prevalence of autoimmune diseases and the rising demand for biologic treatments have fueled the demand for Humira biosimilars.

• Across the globe, research and diagnostic institutes are engaging in initiatives aligned with government organizations due to the increasing occurrence of autoimmune disorders and the subsequent surge in healthcare spending. The National Institutes of Health (NIH) data reveals that autoimmune disorders rank among the top ten causes of heightened mortality rates in women. As a result, concerted efforts are being made to address these health challenges through collaborative endeavors between institutes and government bodies.

Humira Biosimilar Market - Key Insights:

• As per the analysis shared by our research analyst, the global Humira Biosimilar market is estimated to grow annually at a CAGR of around 20.9% over the forecast period (2023-2030)

• The Humira Biosimilar industry is projected to grow at a significant rate due to increasing prevalence of autoimmune diseases and the rising demand for biologic treatments

• Based on Indication type segmentation, Rheumatoid arthritis was predicted to show maximum market share in the year 2022

• Based on Product segmentation, Reference-Based Biosimilars was the leading type in 2022

• On the basis of region, North America was the leading revenue generator in 2022

Humira Biosimilar Market- Segmentation Analysis:

• The Global Humira Biosimilar Market is segmented on the basis of Product, Indication, and Region.

• The market is divided into three categories based on Product: Reference-Based Biosimilars, Biosimilars with Modified Amino Acid Sequences and Interchangeable Biosimilars . In 2022, the Reference-Based Biosimilars segment is projected to dominate the market Reference-Based Biosimilars are developed by directly comparing their characteristics and performance to the reference drug, Humira (adalimumab). They are manufactured using similar cell lines and processes to produce a highly similar product.

• The market is divided into four categories based on Indication: Rheumatoid arthritis, psoriasis, Crohn's disease and others. The Rheumatoid arthritis equipment segment is anticipated to hold the largest share in revenue. Rheumatoid arthritis is autoimmune disease in which the body's immune system mistakenly attacks the synovium, which is the lining of the membranes that surround the joints. This results in chronic inflammation, leading to joint damage, pain, swelling, and stiffness.

• By blocking TNF-α, adalimumab helps to reduce inflammation and slow down the progression of joint damage, thereby providing relief from the symptoms of rheumatoid arthritis and improving the patient's quality of life. Humira biosimilars are used in the treatment of rheumatoid arthritis because they contain a highly similar version of the active ingredient found in the reference drug Humira (adalimumab). Adalimumab is a monoclonal antibody that specifically targets and inhibits tumor necrosis factor alpha (TNF-α), a protein that plays a key role in causing inflammation in the joints in rheumatoid arthritis.

Humira Biosimilar Market - Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Humira Biosimilar Market- Competitive Landscape:

Companies in the Humira biosimilar market are adopting various strategies to gain a competitive edge. These include investing in extensive research and development to ensure the quality and efficacy of their biosimilars, forming strategic partnerships or collaborations to leverage complementary expertise, and expanding their geographic presence to access new markets. Moreover, some companies focus on offering attractive pricing models and excellent after-sales support to attract more customers and enhance their market share.

Recent Developments:

In September 2016, Amjevita (adalimumab-atto) achieved the distinction of being the first FDA-approved biosimilar for Humira. Subsequently, on January 31, 2023, it marked another milestone by becoming the first Humira biosimilar to be launched in the United States. Amjevita is among the approved Humira biosimilars that have received regulatory clearance for treating HS (hidradenitis suppurativa) in adults.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HUMIRA BIOSIMILAR MARKET KEY PLAYERS

• Amgen
• Samsung Bioepis
• Sandoz (a division of Novartis)
• Mylan (now part of Viatris)
• Boehringer Ingelheim
• Pfizer
• Fresenius Kabi
• Coherus BioSciences
• Merck & Co.

GLOBAL HUMIRA BIOSIMILAR MARKET, BY PRODUCT

• Reference-Based Biosimilars
• Biosimilars with Modified Amino Acid Sequences
• Interchangeable Biosimilars

GLOBAL HUMIRA BIOSIMILAR MARKET, BY INDICATION

• Rheumatoid arthritis
• Psoriasis
• Crohn's disease
• Others

GLOBAL HUMIRA BIOSIMILAR MARKET, BY REGION

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Humira Biosimilar Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Humira Biosimilar Market Snippet by Product
  • 2.1.2. Humira Biosimilar Market Snippet by Indication
  • 2.1.3. Humira Biosimilar Market Snippet by Country
  • 2.1.4. Humira Biosimilar Market Snippet by Region
• 2.2. Competitive Insights

3. Humira Biosimilar Key Market Trends

• 3.1. Humira Biosimilar Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Humira Biosimilar Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Humira Biosimilar Market Opportunities
• 3.4. Humira Biosimilar Market Future Trends

4. Humira Biosimilar Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Humira Biosimilar Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Humira Biosimilar Market Landscape

• 6.1. Humira Biosimilar Market Share Analysis, 2022
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Humira Biosimilar Market - By Product

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Product, 2022 & 2030 (%)
  • 7.1.2. Reference-Based Biosimilars
  • 7.1.3. Biosimilars with Modified Amino Acid Sequences
  • 7.1.4. Interchangeable Biosimilars

8. Humira Biosimilar Market - By Indication

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Indication, 2022 & 2030 (%)
  • 8.1.2. Rheumatoid arthritis
  • 8.1.3. Psoriasis
  • 8.1.4. Crohn's disease
  • 8.1.5. Others

9. Humira Biosimilar Market- By Geography

• 9.1. Introduction
  • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
• 9.2. North America
  • 9.2.1. Overview
  • 9.2.2. Humira Biosimilar Key Manufacturers in North America
  • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.2.4. North America Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
  • 9.2.5. North America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.2.6. U.S.
    • 9.2.6.1. Overview
    • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.2.6.3. U.S. Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.2.6.4. U.S. Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.2.7. Canada
    • 9.2.7.1. Overview
    • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.2.7.3. Canada Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.2.7.4. Canada Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
• 9.3. Europe
  • 9.3.1. Overview
  • 9.3.2. Humira Biosimilar Key Manufacturers in Europe
  • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.3.4. Europe Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
  • 9.3.5. Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.3.6. Germany
    • 9.3.6.1. Overview
    • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.6.3. Germany Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.3.6.4. Germany Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.3.7. Italy
    • 9.3.7.1. Overview
    • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.7.3. Italy Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.3.7.4. Italy Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.3.8. United Kingdom
    • 9.3.8.1. Overview
    • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.8.3. United Kingdom Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.3.8.4. United Kingdom Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.3.9. France
    • 9.3.9.1. Overview
    • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.9.3. France Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.3.9.4. France Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.3.10. Russia
    • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.10.2. Russia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.3.10.3. Russia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.3.11. Netherlands
    • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.11.2. Netherlands Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.3.11.3. Netherlands Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.3.12. Sweden
    • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.12.2. Sweden Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.3.12.3. Sweden Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.3.13. Poland
    • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.13.2. Poland Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.3.13.3. Poland Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.3.14. Rest of Europe
    • 9.3.14.1. Overview
    • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
• 9.4. Asia Pacific (APAC)
  • 9.4.1. Overview
  • 9.4.2. Humira Biosimilar Key Manufacturers in Asia Pacific
  • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.4.4. Asia Pacific Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
  • 9.4.5. Asia Pacific Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.4.6. India
    • 9.4.6.1. Overview
    • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.6.3. India Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.4.6.4. India Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.4.7. China
    • 9.4.7.1. Overview
    • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.7.3. China Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.4.7.4. China Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.4.8. Japan
    • 9.4.8.1. Overview
    • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.8.3. Japan Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.4.8.4. Japan Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.4.9. South Korea
    • 9.4.9.1. Overview
    • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.9.3. South Korea Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.4.9.4. South Korea Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.4.10. Australia
    • 9.4.10.1. Overview
    • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.10.3. Australia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.4.10.4. Australia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.4.11. Thailand
    • 9.4.11.1. Overview
    • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.11.3. Thailand Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.4.11.4. Thailand Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.4.12. Indonesia
    • 9.4.12.1. Overview
    • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.12.3. Indonesia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.4.12.4. Indonesia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.4.13. Philippines
    • 9.4.13.1. Overview
    • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.13.3. Philippines Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.4.13.4. Philippines Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.4.14. Rest of APAC
    • 9.4.14.1. Overview
    • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.14.3. Rest of APAC Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.4.14.4. Rest of APAC Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
• 9.5. Latin America
  • 9.5.1. Overview
  • 9.5.2. Humira Biosimilar Key Manufacturers in Latin America
  • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.5.4. Latin America Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
  • 9.5.5. Latin America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.5.6. Brazil
    • 9.5.6.1. Overview
    • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.6.3. Brazil Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.5.6.4. Brazil Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.5.7. Mexico
    • 9.5.7.1. Overview
    • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.7.3. Mexico Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.5.7.4. Mexico Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.5.8. Argentina
    • 9.5.8.1. Overview
    • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.8.3. Argentina Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.5.8.4. Argentina Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.5.9. Colombia
    • 9.5.9.1. Overview
    • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.9.3. Colombia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.5.9.4. Colombia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.5.10. Rest of LATAM
    • 9.5.10.1. Overview
    • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
• 9.6. Middle East and Africa
  • 9.6.1. Overview
  • 9.6.2. Humira Biosimilar Key Manufacturers in Middle East and Africa
  • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.6.4. Middle East and Africa Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
  • 9.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.6.6. Saudi Arabia
    • 9.6.6.1. Overview
    • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.6.7. United Arab Emirates
    • 9.6.7.1. Overview
    • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.6.8. Israel
    • 9.6.8.1. Overview
    • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.8.3. Israel Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.6.8.4. Israel Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.6.9. Turkey
    • 9.6.9.1. Overview
    • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.9.3. Turkey Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.6.9.4. Turkey Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.6.10. Algeria
    • 9.6.10.1. Overview
    • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.10.3. Algeria Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.6.10.4. Algeria Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.6.11. Egypt
    • 9.6.11.1. Overview
    • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.11.3. Egypt Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.6.11.4. Egypt Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.6.12. Rest of MEA
    • 9.6.12.1. Overview
    • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.12.3. Rest of MEA Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.6.12.4. Rest of MEA Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Humira Biosimilar Industry

• 10.1. Competitive Dashboard
• 10.2. Company Profiles
  • 10.2.1. Amgen
  • 10.2.2. Samsung Bioepis
  • 10.2.3. Sandoz (a division of Novartis)
  • 10.2.4. Mylan (now part of Viatris)
  • 10.2.5. Boehringer Ingelheim
  • 10.2.6. Pfizer
  • 10.2.7. Fresenius Kabi
  • 10.2.8. Coherus BioSciences
  • 10.2.9. Merck & Co.

11. 360 Degree Analyst View

12. Appendix

• 12.1. Research Methodology
• 12.2. References
• 12.3. Abbreviations
• 12.4. Disclaimer
• 12.5. Contact Us

관련자료